Cholangiocarcinoma: The Present and Future of Targeted Therapies

A. Kalyan, R. Shroff
{"title":"Cholangiocarcinoma: The Present and Future of Targeted Therapies","authors":"A. Kalyan, R. Shroff","doi":"10.17925/ohr.2022.18.1.9","DOIUrl":null,"url":null,"abstract":"Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. CCAs tend to metastasize with early lymph node involvement lending to poor surgical outcomes and need for systemic therapy. Given the paucity of successful therapies in these cancers, it is important to understand the molecular drivers and to develop therapeutic strategies using targeted therapies either alone or in combination. The molecular landscape offers several new potentially targetable drivers.","PeriodicalId":249239,"journal":{"name":"Oncology & Haematology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology & Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/ohr.2022.18.1.9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. CCAs tend to metastasize with early lymph node involvement lending to poor surgical outcomes and need for systemic therapy. Given the paucity of successful therapies in these cancers, it is important to understand the molecular drivers and to develop therapeutic strategies using targeted therapies either alone or in combination. The molecular landscape offers several new potentially targetable drivers.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胆管癌:靶向治疗的现在和未来
胆管癌(CCAs)是一种起源于胆道上皮的异质性肿瘤。cca易于转移,早期淋巴结受累,导致手术效果差,需要全身治疗。鉴于这些癌症缺乏成功的治疗方法,了解分子驱动因素并开发单独或联合使用靶向治疗的治疗策略非常重要。分子领域提供了几个新的潜在目标驱动因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Zanubrutinib for the Treatment of B-cell Malignancies Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression Pafolacianine: A Diagnostic Agent to Identify Lung Cancer Lesions in Adults with Known or Suspected Lung Cancer Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1